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Abstract. Objectives: This study examined the indicat-
ions, efficacy and outcomes of implantable cardioverter
defibrillator (ICD) use in the pediatric population.
Background: ICDs are first-line therapy for adults re-
suscitated from sudden cardiac death (SCD) or at high
risk for life-threatening ventricular arrhythmias. Use
of ICDs in children and young adults is infrequent and
there are few data regarding this group.
Methods: We abstracted and analyzed data for all
patients in whom ICDs were implanted.
Results: A total of 38 devices were implanted in
27 patients. Age ranged from 6 to 26 years (mean, 14)
and weight ranged from 16 to 124 kg (mean, 47). Di-
agnoses included long QT syndrome (9), hypertrophic
cardiomyopathy [6], repaired congenital heart disease
[5], and idiopathic ventricular tachycardia/fibrillation
[4]. Indications comprised resuscitated SCD [15], syn-
cope [9], and life-threatening ventricular arrhythmia
[3]. Initial device placement was infraclavicular in 13,
abdominal in 13 and intrathoracic in 1. Epicardial
leads were used with 5 systems. A single coil lead
was used in 17. Seven patients, all previously resusci-
tated from SCD, experienced 88 appropriate success-
ful discharges. There were 6 inappropriate discharges
in 3 patients. Mean time to device replacement was
3.1 years (n = 11). Complications included 2 infected
systems, 2 lead dislodgments, 2 lead fractures, 1 post-
pericardiotomy syndrome, 1 adverse event with defib-
rillation threshold (DFT) testing, and 1 patient with psy-
chiatric sequelae. No deaths occurred with implanted
ICDs.
Conclusions: These data demonstrate that ICDs pro-
vide safe and effective therapy in young patients. The
indications for ICDs as primary preventive therapy
remain uncertain.
Key Words. children, implantable cardioverter defib-
rillator, sudden cardiac death, ventricular arrhythmia
Introduction
Since Mirowski and associates [1] reported the
first use of implantable cardioverter-defibrillators
(ICDs) in 1980, these devices have become a widely
accepted therapy for patients who have survived
aborted sudden cardiac death (SCD). The MADIT
[2] and MUSTT trials [3] demonstrated the use-
fulness of ICDs for primary prevention of SCD in
certain high-risk populations. In 1989, Kral and
colleagues [4] reported the first use of ICDs in
young patients. Since this initial report, ICD use
in pediatric patients has increased substantially,
paralleling the increase in adults. The increased
use has been due in part to technologic advance-
ments, including smaller devices and electrodes,
transvenous lead systems, improved detection al-
gorithms, expanded diagnostic storage capabili-
ties, single coil configurations using the generator
as the second high voltage electrode, and devices
with dual chamber pacing and sensing capabili-
ties. Additionally, identification of children at high
risk for SCD has expanded, resulting in implanta-
tion of ICDs as a primary preventive measure.
Pediatric patients, however, still represent less
than 1% of all persons with ICDs [5] and the clini-
cal experience in young patients remains limited.
Previous reports have consisted of retrospective
surveys of multiple institutions [6–9], small series
[10–15], and case reports [16,17]. The purpose of
this study is to report a single center’s experience
with this evolving technology and to provide data
on the indications, efficacy and outcomes of ICD
use in young patients.
Methods
The patient database was queried for all indi-
viduals in whom an ICD was implanted at the
University of Michigan Congenital Heart Cen-
ter. Medical records, electrocardiograms, Holter
tracings, electrophysiologic studies, implanta-
tion data, telemetered data, and interrogation
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data were abstracted for these individuals. In-
dications for ICD implant and clinical histo-
ries were reviewed. Device type and configura-
tion, pacing parameters, defibrillation thresholds
(DFTs), device activity, and complications were
recorded.
Mean, standard deviation and median values
were calculated for patient demographic vari-
ables, follow-up intervals and defibrillation
thresholds. Freedom from first appropriate
defibrillation discharge, freedom from inap-
propriate defibrillation discharge and freedom
from ICD-related complication were assessed by
Kaplan-Meier analysis using Graph Pad Prism
Version 3.00 (Graph Pad Software, Inc., San
Diego, CA). Implant and post-implant follow-up
DFTs were compared using unpaired Student t
tests.
Results
Between October, 1992 and June, 2001, a to-
tal of 38 devices were implanted in 27 patients
(Table 1). There were 14 (52%) females. The age
at implantation ranged from 6.2 to 26.3 years
(mean, 14.5 ± 4.4; median, 14.6 years). The weight
of the patients ranged from 16 to 124 kg (mean,
49 ± 21; median, 47 kg). The mean follow up in-
terval was 32 ± 29 months (range, 1–100; median,
24 months). The diagnoses of the 27 patients
in whom ICDs were implanted are summarized
in Table 1. The most frequent diagnoses were long
QT syndrome (n = 9, 33%), hypertrophic cardiomy-
opathy (n = 6, 22%), repaired complex congenital
heart disease (n = 5, 19%), and idiopathic ven-
tricular tachycardia/ventricular fibrillation (n = 4,
15%). The remaining 3 devices were implanted
in a patient with coronary arteriopathy and car-
diomyopathy following an orthotopic heart trans-
plantation, a patient with Marfan syndrome, and
a patient with arrhythmogenic right ventricular
dysplasia. Surgical repairs for patients with con-
genital heart disease included transannular out-
flow tract patch for tetralogy of Fallot (n = 2),
Mustard procedure (n = 1) for transposition of
the great arteries, intraventricular tunnel for
double outlet right ventricle (n = 1), and arte-
rial switch operation and ventricular septal de-
fect closure for double outlet right ventricle with
subpulmonary ventricular septal defect (Taussig-
Bing anomaly; n = 1). Three of the 6 individuals
with hypertrophic cardiomyopathy had undergone
myectomy.
Indications for initial ICD placement in the
27 patients (Table 1) were grouped into three
categories: (1) resuscitated sudden cardiac death
(SCD; n = 15), (2) syncope (n = 9), and (3) life-
threatening ventricular arrhythmia (n = 3), de-
fined as ventricular tachycardia or fibrillation
on Holter or during electrophysiologic testing.
The patients in whom the initial indication was
syncope or life-threatening ventricular arrhyth-
mia were also considered the primary prevention
group as they had not experienced resuscitated
SCD (n = 12). Seven of the 9 individuals with long
QT syndrome and all of the individuals with id-
iopathic ventricular tachycardia/fibrillation expe-
rienced out-of-hospital resuscitated SCD. Of the
9 individuals with syncope, 6 had documented
ventricular tachycardia or fibrillation either on
electrocardiographic monitoring or during electro-
physiologic study. Among the remaining 3 individ-
uals with syncope, 2 had long QT syndrome and
a family history of SCD, and 1, in whom a dual
chamber ICD was implanted, had hypertrophic
cardiomyopathy, rapidly progressive left ventric-
ular outflow tract obstruction and non-sustained
ventricular tachycardia.
Initial ICD placement was infraclavicular in
13 patients (48%), abdominal in 13 (48%) and in-
trathoracic in 1 (4%). With two exceptions, replace-
ment devices were placed in the pocket created for
the original device. Among the 13 initial abdom-
inal implants, 9 utilized transvenous leads tun-
neled from the subclavian area (Fig. 1). Six of the
initial infraclavicular devices were placed beneath
the pectoralis muscle. Infraclavicular ICD place-
ment was used in patients as young as 7 years
and as small as 30 kg.
Thirty-three lead systems were placed in the
27 patients, of which 28 were transvenous. Re-
placement leads were implanted for increased lead
impedance in 3 patients and for exchanging epi-
cardial for endocardial systems in 3 patients. Of
the 28 transvenous lead systems, a single coil to
active device (“hot can”) configuration was used
in 17 and a dual coil configuration in 11. Of the
17 generators serving as the second electrode, 7
were placed in an abdominal pocket and 10 in an
infraclavicular pocket. The youngest and smallest
patients to receive transvenous leads were 7 years
and 22 kg, respectively. An active device configura-
tion was used in patients as young as 7 years and
as small as 24 kg. In 3 patients, lead extenders
were utilized to tunnel endocardial leads from the
infraclavicular region to abdominally located de-
vices (Fig. 1). The only epicardial system placed in
the last six years was in a 16 kg child.
DFTs were obtained using a basic stepdown
protocol (n = 33) and at implant ranged from 5 J
to 21 J (mean, 11 ± 5; median, 10 J). Follow-up
DFTs, 6–8 weeks after implant (n = 19), ranged
from 5 J to 20 J (mean, 13 ± 5 J; median 11;
p = 0.13). There were no significant differences in
the implant or follow-up mean DFTs related to the
device position, lead configuration or use of a lead
extender.
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Fig. 1. Radiograph of patient 2 demonstrating transvenous leads tunneled from the infraclavicular region to an ICD placed in the
left upper quadrant. The use of lead extenders may permit future placement of an infraclavicular device without removal of the
endocardial leads. This is an active device configuration between the abdominally placed device and the coil placed along the right
ventricular diaphragmatic surface.
Seven of the 27 (26%) patients experienced a
total of 88 appropriate successful ICD discharges
(Fig. 2A). Appropriate discharges were confirmed
by ICD telemetry and defined as ventricular tachy-
cardia or fibrillation accurately detected accord-
ing to the programmed recognition cycle lengths
and number of cycles. Among these 7 patients, 4
had long QT syndrome (63 discharges) and 1 each
had hypertrophic cardiomyopathy (2 discharges),
congenital heart disease (16 discharges) and idio-
pathic ventricular tachycardia/fibrillation (7 dis-
charges). A single patient with long QT syndrome
was defibrillated 45 times over a 48 hour time
period during a “torsades storm.” Overdrive ven-
tricular pacing controlled her arrhythmia. All 7 of
these patients underwent initial device placement
for secondary prevention of SCD; their initial clini-
cal indication was resuscitated SCD. No patient in
whom the initial clinical indication was syncope or
life-threatening ventricular arrhythmia (primary
prevention of SCD) experienced an appropriate
discharge during the follow-up period.
Three (11%) patients experienced a total of 6
inappropriate discharges (Fig. 2B). One patient
whose device discharged inappropriately was
found to have a fractured sensing lead. Rapid mo-
tion of her left arm generated electrical noise that
was misinterpreted as ventricular fibrillation by
the device and resulted in an inappropriate device
discharge. The faulty lead was replaced and the
patient has experienced no further discharges.
One patient received three inappropriate dis-
charges due to atrial tachycardia misinterpreted
as ventricular tachycardia. The patient subse-
quently had a dual chamber device implanted
with resolution of the inappropriate arrhythmia
detection. The third patient was shocked twice
during fast sinus tachycardia with frequent ven-
tricular premature beats. Reprogramming of the
device to a shorter sensed ventricular fibrillation
cycle length corrected the problem.
Two (7%) of the patients received unsuccessful
initial ICD discharges and were successfully de-
fibrillated by subsequent programmed therapies.
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Fig. 2. Kaplan-Meier analysis for freedom from appropriate device discharge (A), freedom from inappropriate device
discharge (B), and freedom from ICD-related complication (C).
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A patient with idiopathic ventricular tachycar-
dia/fibrillation was defibrillated 7 times; on 2 of
those occasions, the first 20 J shock was unsuccess-
ful in restoring sinus rhythm. Subsequent 30 J dis-
charges were successful and the device has since
been reprogrammed to deliver a 30 J initial shock.
A patient with LQTS was successfully defibril-
lated 3 times and experienced a total of 12 un-
successful discharges. Following the last event,
the device was removed and a new ICD capable
of delivering a biphasic shock waveform was im-
planted. Both of these patients had low initial and
follow-up DFTs at testing, 5 J and 10 J, and 15 J
and 15 J, respectively.
Eleven devices were replaced during the study
time period, with a range of time to replacement of
11 months to 5.7 years (mean, 3.2 ± 1.4; median,
3.2 years). Indications for replacement included
generator elective replacement time (n = 4), up-
dating device technology (n = 5), lead change and
approaching elective replacement time (n = 1),
and recall of a device (n = 1). Among the 5 ICDs
replaced to update technology, 4 were to add an
Fig. 3. Radiograph of patient 11. The proximal coil of the dual coil transvenous lead is fractured at the junction of the clavicle
and 1st rib (see text).
atrial lead for dual chamber sensing and pacing
and 1 was to deliver a biphasic shock waveform.
Nine complications related to the ICD sys-
tems occurred in 7 patients (26%; Fig. 2C). There
were 2 infected systems requiring removal within
1 month of placement. Two transvenous leads be-
came dislodged; one lead was repositioned in the
right ventricle, and 1, in 1993, was replaced with
an epicardial lead. Two transvenous leads have
fractured. One, a fractured sensing lead, resulted
in an inappropriate discharge and was replaced.
The second sustained a fracture in the proxi-
mal coil of a dual coil transvenous lead (Fig. 3).
The device was reprogrammed to use the gen-
erator as the second high voltage electrode and
the patient has received successful appropriate
discharges using this configuration. One patient
had post-pericardotomy syndrome following im-
plantation of an epicardial lead system. Follow-
ing implantation of a replacement device several
years later, the same patient experienced severe
bradycardia and hypotension during anesthesia
induction for post-implant, follow-up DFT testing,
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requiring extensive resuscitative efforts and an in-
tensive care unit admission. One patient with long
QT syndrome and severe neurologic impairment
following resuscitated SCD died suddenly 2 years
after explant of an infected device; her parents had
refused implantation of a second ICD. No patient
with an implanted device died. Finally, one patient
has suffered from severe post-traumatic stress
disorder.
Discussion
The need for ICDs in children and young adults
is infrequent. Secondary prevention of resusci-
tated SCD is a widely accepted indication. In con-
trast, device implantation for primary prevention
of SCD remains controversial. Advances in the
recognition of genetic conduction system disor-
ders associated with SCD (e.g., long QT syndrome,
Brugada syndrome and arrhythmogenic right ven-
tricular dysplasia) and improving stratification of
patients at risk for SCD (e.g., hypertrophic car-
diomyopathy and repaired congenital heart dis-
ease) have contributed to the increase in use of
ICDs in children for primary prevention of SCD.
Despite these developments, as demonstrated by
our experience and that of others, prospective
identification of children and young adults at risk
of SCD remains difficult and confounds the use of
ICDs for primary prevention of SCD in this popu-
lation [18].
Secondary prevention of SCD, in patients with
long QT syndrome, hypertrophic cardiomyopathy,
repaired congenital heart disease, and idiopathic
ventricular tachycardia/fibrillation, was the most
common indication for ICD implantation in our
patients. Twelve of 27 (44%) and 10 of the last
13 initial implants, however, have been in individ-
uals who have not experienced resuscitated SCD,
and in whom the indication was considered pri-
mary prevention of SCD.
Certain technologic advancements have proven
particularly germane to pediatric patients. The
most obvious is the reduction of device size from
300 cc to < 35 cc over the last 10 years. Smaller
device size has obviated the need for abdominal
device placement in all but the smallest patients.
Smaller diameter transvenous leads and shorter
single coil leads have also permitted implantation
of ICD systems in smaller patients without thora-
cotomy. Innovative configurations, such as a sin-
gle coil transvenous lead placed along the right
ventricular diaphragmatic surface linked to an ab-
dominally placed device as the second high voltage
electrode, allow deployment in smaller patients
(Fig. 1). This arrangement, which has been uti-
lized in 6 of our patients, has been associated with
low DFTs (mean, 11 J), 4 appropriate successful
discharges and no unsuccessful discharges [14].
Due to the increased morbidity associated with
epicardial lead systems, our current practice is to
implant transvenous systems in all but the small-
est patients and in those in whom there is no ve-
nous access. To date, we have used a transvenous
lead system in a patient as small as 22 kg.
DFTs have been consistently low in our patients
irrespective of lead configuration. No patient has
required the placement of an extra superior vena
cava coil or a subcutaneous array in order to lower
DFTs. Controversy exists concerning the neces-
sity of post-implant DFT testing in pediatric pa-
tients. Post-implant DFT testing involves patient
inconvenience, discomfort, and expense, in addi-
tion to the inherent risks of anesthesia, ventric-
ular arrhythmia induction and defibrillation. Of
the 27 patients in this series, one with long QT
syndrome developed a profound bradyarrhythmia
with hemodynamic collapse requiring extensive
resuscitation prior to the induction of ventricular
tachycardia/fibrillation for DFT testing. In addi-
tion, no patient in our cohort required reprogram-
ming of their device based on the results of DFT
testing [19]. Based on this experience and reports
suggesting that follow-up DFT testing is most ap-
propriately reserved for individuals in whom de-
vice dysfunction is suspected [20], we no longer
perform routine follow-up DFT testing.
Only three (11%) of our patients experienced
inappropriate discharges, a proportion lower than
previously reported in young patients [4,6–8,11].
Expanded sensing and programming capabilities
and the use of dual chamber devices has resulted
in improved discrimination between sinus tachy-
cardia or atrial arrhythmias and ventricular ar-
rhythmias. This rate of inappropriate discharges
compares with a reported rate of approximately
5% in large adult series [21]. Differentiation of
sinus tachycardia from ventricular tachyarrhyth-
mias is particularly important in pediatric pa-
tients, as they may achieve sinus rates approach-
ing or exceeding 200 beats per minute. Treadmill
exercise testing is useful in determining the ap-
propriate high rate zone for individual patients.
While only 7 of the 27 patients (26%) in this
series received appropriate device discharges,
among the 16 patients with at least 2 years fol-
low up, 7 (44%) were appropriately and success-
fully defibrillated. This finding is consistent with
other reports, in which 40–60% of young patients
with ICDs received appropriate device discharges
within 1.5–2 years of implantation [6–9,11]. Be-
cause younger patients have the potential for con-
siderable longevity and thus a longer period of
risk, lower appropriate shock rates are acceptable.
Complex cardiac and systemic disorders in
some pediatric patients requiring ICDs may ne-
cessitate creative device configurations [15]. One
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patient in our series has Eagle-Barrett (prune
belly) syndrome, renal failure requiring a kidney
transplant and idiopathic ventricular tachycar-
dia/fibrillation. Due to the absence of abdominal
musculature and his small size, the ICD was im-
planted intrathoracically utilizing an epicardial
lead system (Fig. 4). His device was subsequently
replaced, at which time he had grown sufficiently
to allow the placement of an infraclavicular device
and transvenous leads.
Prior reports of ICDs in the young have de-
scribed complication rates requiring system revi-
sions in 29% [8] and 45% [22] of patients. In our
series, 7 of the 27 (26%) of the patients have expe-
rienced a total of 9 device-related complications.
Five of the complications (19%) necessitated sys-
tem revisions. Two of the 27 (7%) patients devel-
oped a pocket infection requiring device explant.
Link et al. [22] previously reported an infection
rate of 18% in pediatric patients undergoing ICD
implant. The infection rate in their experience was
higher than that observed in adult patients who
underwent device implantation by the same physi-
cians, during the same time period and in the same
laboratory. The cause of the increased incidence of
Fig. 4. Posteroanterior (A) and lateral (B) chest radiographs of patient 12, in whom intrathoracic device placement was
necessitated by the absence of abdominal musculature (Eagle-Barrett syndrome) and small size.
infection among their pediatric patients was not
identified. Finally, one of the patients in our co-
hort experienced a lead dislodgment and under-
went successful reimplantation of the indwelling
lead. To avoid this particular complication, we use
active fixation defibrillation leads in the ventricle.
The potential for life-threatening arrhythmia
and receiving or anticipating ICD discharges
are sources for considerable anxiety, particu-
larly for children. Three patients who were re-
peatedly shocked experienced anxiety that per-
sisted for more than one month. Two patients
developed school phobias. One patient developed
post-traumatic stress disorder, requiring antide-
pressant and anxiolytic medication with ongoing
psychiatric therapy. All of our patients participate
in support groups and most attend a national an-
nual retreat for young patients and children with
ICDs [23].
In summary, the indications and use of ICDs in
the pediatric population are expanding. Improved
device and lead technology combined with ear-
lier identification of patients at risk for SCD has
contributed to this increase. This report, though
smaller than adult series, represents the largest
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Fig. 4. (Continued)
single center pediatric series to date and demon-
strates the applicability of ICD systems in this
population. While primarily designed for use in
adult patients, these devices can be configured in
a variety of ways to suit a diversity of young pa-
tients. With careful programming of the arrhyth-
mia detection parameters, ICDs can be used safely
and effectively in children and young adults resus-
citated from SCD. However, for the use of ICDs
as primary prevention in children, the indications
remain unclear and the efficacy uncertain.
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